Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

New Potential Therapy for Diabetic Kidney Disease: Galectin Therapeutics Announces Anti-Galectin Drug is Effective in



  New Potential Therapy for Diabetic Kidney Disease: Galectin Therapeutics
  Announces Anti-Galectin Drug is Effective in Preclinical Studies

Business Wire

NORCROSS, Ga. -- January 22, 2013

Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics
that target galectin proteins to treat fibrosis and cancer, today announced
new preclinical data on the efficacy of anti-galectin therapy on diabetic
kidney disease. Treatment of diabetic mice with GR-MD-02 was found to reverse
the primary kidney disease associated with diabetes, called diabetic
nephropathy, the leading cause of kidney failure, dialysis and kidney
transplant. GR-MD-02 is the Company’s lead galectin inhibitor in development
for the treatment of liver fibrosis, including non-alcoholic steatohepatitis
(NASH) liver disease.

“These data extend the potential therapeutic use of GR-MD-02 into diabetic
kidney disease, a progressive disorder resulting in kidney scarring and
ultimately kidney failure,” said Peter G. Traber, MD, President, Chief
Executive Officer and Chief Medical Officer, Galectin Therapeutics Inc. “These
findings show the broad potential of GR-MD-02 for treating organ fibrosis
which positions us to develop partnerships with companies focused on kidney
disease, while we continue our focus on development for the treatment of liver
fibrosis.”

In the preclinical study, diabetic mice developed histological findings
consistent with diabetic nephropathy, consisting of glomerular lesions in the
form of diffuse mesangial matrix accumulation and proliferation. The kidneys
of the diabetic mice also showed fibrosis evidenced by interstitial collagen
deposition. Treatment with GR-MD-02 reduced the mesangial matrix accumulation,
which suggests the drug suppressed the production and/or accumulation of
extracellular matrix components. Additionally, GR-MD-02 markedly reduced the
area of interstitial fibrosis. These results demonstrate the anti-fibrotic
efficacy of GR-MD-02 in the kidney and its therapeutic potential in diabetic
nephropathy as well as other chronic kidney diseases.

About Diabetic Kidney Disease

Diabetic Nephropathy is the leading cause of dialysis and kidney
transplantation. It is a progressive kidney disease caused by angiopathy of
capillaries in the kidney glomeruli. It is characterized pathologically as a
diffuse glomerulosclerosis which results in proteinuria, nephrotic syndrome,
progressive reduction in glomerular filtration rate, and results eventually in
kidney failure. Diabetic nephropathy is due to longstanding diabetes mellitus
and is the major indication for dialysis in many Western countries. While
control of serum glucose level and control of blood pressure are effective in
reducing the progression of diabetic nephropathy, renal failure remains a
major health problem. Accordingly,  there is a great need to provide therapies
that are efficacious in preventing, slowing the progression or reversing
diabetic nephropathy and kidney fibrosis.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. Factors that could
cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others: incurrence of operating
losses since our inception, uncertainty as to adequate financing of our
operations, extensive and costly regulatory oversight that could restrict or
prevent product commercialization, inability to achieve commercial product
acceptance, inability to protect our intellectual property, dependence on
strategic partnerships, product competition, and others stated in risk factors
contained in our SEC filings. We cannot assure that we have identified all
risks or that others may emerge which we do not anticipate. You should not
place undue reliance on forward-looking statements. Although subsequent events
may cause our views to change, we disclaim any obligation to update
forward-looking statements.

Contact:

Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO, & CMO
ir@galectintherapeutics.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement